En esta edición las ponencias estarán disponibles desde el día 2 de febrero de 2022 en nuestra web.
El contenido se organizará por bloques temáticos:
Conferencia de apertura
Recomendaciones clínicas para la práctica del deporte en personas con diabetes mellitus (Guía RECORD). Actualización 2021
Dr. Manuel Gargallo Fernández
Coordinador del Comité Gestor del Área de Diabetes de la SEEN
Módulo 1. Sesiones plenarias
Módulo 1. Sesiones plenarias
Moderador: Dr. Manuel Muñoz Torres
Dr. Alberto Moreno
ADA 2021: Are We There Yet? Initiating SGLT2 Inhibitors and/or GLP-1RAs in the Inpatient Cardiovascular Setting.
ADA 2021: Time to Consider Initiating SGLT2 Inhibitors and/or GLP-1RAs in the Inpatient Cardiovascular Care Setting—And Here’s How. Sandeep Das.
ADA 2021: Caution before Universally Recommending Initiation of SGLT2 Inhibitors and/or GLP-1RAs in the Inpatient Cardiovascular Care Setting Speaker: Jennifer Green.
Dr. Elías Delgado
EASD 2021: Session: Michael Berger debate: Who suffers more: Are women with diabetes at higher cardiovascular risk? Chair: Alexandra Kautzky-Willer.
Dr. Javier Escalada
EASD 2021: 36th Camillo Golgi Lecture. Personalising the treatment for patients with type 2 diabetes: the mean is meaningless. Hiddo Lambers Heerspink.
Dra. Rebeca Reyes
EASD 2021: Preventing diabetic complications – 100 years on from insulin: Which of the newer classes will prevail? S60.
EASD 2021: Michael A. Nauck: 100 years later, it’s GLP-1 receptor agonists. John Wilding: 100 years later, it’s SGLT2 inhibitors.
Dra. Sharona Azriel
ADA 2021: Joint ADA/ASN Symposium—New Therapies for Kidney Protection in Diabetes. Chair, D Cherney.
ADA 2021: Realizing the Benefits of SGLT2 Inhibition for Kidney Protection. V Perkovic.
- Do GLP-Protect the Kidney? O Mosenzon.
- Kidney Benefits of Mineralocorticoid Receptor Antagonism—Lessons from FIDELIO-DKD. G Bakris.
- Combination Therapies for Kidney Protection in Diabetes—Is One Plus One More than Two? HL Heerspink.
Módulo 2. Epidemiología, genética, obesidad y otros factores de riesgo
Módulo 2. Epidemiología, genética, obesidad y otros factores de riesgo
Moderador: Dr. José María Hernández Anguera
Dr. Alberto Moreno
ADA 2021: 131-OR: ADA Presidents’ Select Abstract: Effect of Insulin Degludec vs. Insulin Glargine U100 on Occurrence of Nocturnal Hypoglycemia Assessed by Nocturnal Plasma Glucose Profiles in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia. Julie M. Brøsen.
ADA 2021: 299-OR: Relative Contribution of Statin Intensity, Low-Density Lipoprotein Cholesterol Level and Duration of Statin Therapy for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes. Ji Yoon Kim.
Dr. Elías Delgado
EASD 2021: Cardiovascular events in patients with metabolically healthy obesity. A nationwide cohort study. G. Fauchier, A. Bisson, C. Semaan, J.Herbert, A.Bodin, D.angoulvant, PH. Ducluzeau, GYH. Lip, L. Fauchier.
EASD 2021: High intensity interval training improves insulin sensitivity and affects mitochondria dynamics in skeletal muscle of type 2 diabetes humans.
Dr. Javier Escalada
EASD 2021: Visceral adipose tissue mitochondrial function is reduced in humans with non-alcoholic fatty liver disease and correlates with insulin resistance.
EASD 2021: Non-invasive prenatal diagnosis of fetal genotype in pregnant women with GCK-MODY: the impact of precision medicine on antenatal care.
Dra. Rebeca Reyes
ECE 2021: Type 2 diabetes clusters indicate diabetes duration key in fracture risk.
ENDO 2021: Early Onset Acceleration of Fetal Growth in Gestational Diabetes Mellitus: Deciding About When and Whom to Screen for Preventing Fetal Macrosomia.
Dra. Sharona Azriel
ADA 2021: STEP 2 TRIAL: Post hoc Analysis.
Módulo 3. Clínica y tratamiento (I)
Módulo 3. Clínica y tratamiento (I)
Moderador: Dr. Pedro Mezquita Raya
Dr. Alberto Moreno
ADA 2021: 189-OR: FIDELIO-DKD Study: Analysis of Effects of Finerenone by Baseline A1C. Ellen Burgess.
ADA 2021: 299-OR: Similar Hypoglycemia Duration with Once-Weekly Insulin Icodec vs. Insulin Glargine U100 in Insulin Naïve or Experienced Patients with T2D. Robert J. Silver.
Dr. Elías Delgado
EASD 2021: Major results from the Glycaemia Reduction Approaches in Diabetes: a Comparative Effectiveness (GRADE) Study. Chair: S.E. Kahn, USA.
- D.M. Nathan, USA: Background, rationale, design, conduct, adherence
- J.B. Buse, USA: Major results: Metabolic, microvascular and cardiovascular with subgroup analyses
- M.A. Tiktin, USA: Side-effects / Adverse events / QOL
- N. Younes, USA: Heterogeneity of treatment effects including baseline factors associated with success
- D.R. Matthews, UK: Discussan.
EASD 2021: Results from TriMASTER: a 3-way cross-over trial of precision medicine strategy of 2nd/3rd line therapy in type 2 diabetes. Chair: N. Sattar, UK.
- A.T. Hattersley, UK: Precision medicine approaches in type 2 diabetes based on how clinical features influence glycaemic treatment response.
- E.R. Pearson, UK: Trial designs to test precision medicine approaches.
- C. Angwin, UK: Design of the TriMASTER trial.
- B.M. Shields, UK: Results of the TriMASTER trial.
- A.T. Hattersley, UK: Clinical and methodological implications of TriMASTER trial results
- C.M. Kistorp, Denmark: Commentary Panel Q&A.
Dr. Javier Escalada
EASD 2021: Management of type 1 diabetes: ADA-EASD Consensus Report 2021. Total costs of care in patients with type 2 diabetes and cardiovascular disease: a comparative cohort study (OFFSET).
EASD 2021: Total costs of care in patients with type 2 diabetes and cardiovascular disease: a comparative cohort study (OFFSET).
Dra. Rebeca Reyes
EASD 2021: Effect of tirzepatide versus insulin degludec on glycaemic control captured with continuous glucose monitoring in patients with type 2 diabetes (SURPASS-3 CGM).
ENDO 2021: Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11.
ECE 2021: Relationship between calibration accuracy and glycaemic variability on CGM.
Dra. Sharona Azriel
ADA 2021: Volagidemab, a Human Monoclonal Glucagon Receptor Antagonist, improves glycemic control in people with DM1: a 12-week, randomized, double-blind, placebo-controlled trial. OR-236. Pettus J, Boeder S, Christiansen M, et al.
ADA 2021: Closed-Loop Increases Time-in-Range in Older Adults with Type 1 Diabetes Compared with Sensor-Augmented Pump Therapy (ORACL): A Randomized Crossover Trial. OR-212. McAuley S.A, Trawley S, Vogrin S, et al.
Módulo 4. Clínica y tratamiento (II)
Módulo 4. Clínica y tratamiento (II)
Moderador: Dr. Francisco Tinahones Madueño
Dr. Alberto Moreno
ADA 2021: 101-OR Efficacy and Safety of Once-Weekly Semaglutide 2.0 vs. 1.0 mg for Type 2 Diabetes: SUSTAIN FORTE Randomized Trial JP Frias.
ADA 2021: Session: Update on SCORED and SOLOIST Cardiovascular and Kidney Outcomes Trials. Meta-analysis of SOLOIST. and SCORED. Deepak Bhatt. Renal Effects of Sotagliflozin. Julia Lewis. Sotagliflozin Background and Study Designs of SOLOIST and SCORED. Lawrence Leiter.
Dr. Elías Delgado
EASD 2021: Maternal efficacy, safety, and pregnancy outcomes with degludec vs detemir in the treatment of pregnant women with type 1 diabetes: an international, multicentre, randomised trial E.R. Mathiesen, R. Corcoy, F. Dunne, M. Ekelund, D.S. Feig, M. Hod, T. Jia, B. Kalyanam, S. Kar, A. Kautzky-Willer, P. Damm, on behalf of the EXPECT study group, Denmark, Spain, Ireland, Canada, Israel, India, Austria.
EASD 2021: Comparative effectiveness of insulin glargine 300 U/mL and insulin degludec 100 U/mL in insulin naive type 2 diabetes adults: the Restore2 naive cohort.
EASD 2021: Similar hypoglycaemia duration with once-weekly insulin icodec vs insulin glargine U100 in insulin naive or experienced patients with type 2 diabetes.
Dr. Javier Escalada
EASD 2021: A clinical-genetic score for predicting type 2 diabetes remission after bariatric surgery: the OBEGEN Project.
EASD 2021: Remission of type 2 diabetes following a short-term intervention with insulin glargine and metformin/sitagliptin: results of the REMIT-sita randomised controlled trial.
Dra. Rebeca Reyes
EASD 2021: Efficacy and safety of tirzepatide versus semaglutide once weekly as add-on therapy to metformin in people with type 2 diabetes (SURPASS-2).
EASD 2021: Efficacy and safety of tirzepatide, a dual GIP/GLP-1 receptor agonist, compared to insulin degludec in patients with type 2 diabetes (SURPASS-3).
EASD 2021: Tirzepatide, a dual GIP/GLP-1 receptor agonist, is effective and safe when added to basal insulin for treatment of type 2 diabetes (SURPASS-5).
Dra. Sharona Azriel
ADA 2021: Glycemic Control with once weekly Basal Insulin Fc (BIF) in persons with Type 2 Diabetes Mellitus using Continuous Glucose Monitoring (CGM) in a Phase 2 Study. OR-192. Kazda C, Chien J, Zhang Q, et al.
ADA 2021: Is Continuous Glucose Monitoring (CGM) an Effective Diabetes Management Tool in Primary Care? Co-Chairs, RM Bergenstal, E Wright.
Conferencia de cierre
Medicina de Precisión en diabetes ¿quo vadis?
Dr. Javier Escalada San Martín
Presidente de la SEEN
El ARC culminará el día 12 de febrero a las 10:00 h. con una sesión de debate en directo que se retransmitirá por streaming y en la que podrás interactuar con los ponentes para formar parte activa del mismo.
La información contenida en esta página está dirigida únicamente a los profesionales sanitarios aptos para prescribir o dispensar medicamentos. La correcta utilización de su contenido requiere de formación como profesional sanitario.
